Qufora expects French approval in 2022, trains sights on million-dollar business
FRENCH ELECTION: An aging population and a gradual shift towards the idea of treating people in their own homes has led to intense work for Danish medtech firm Qufora, which is aiming for a revenue of DKK 20-40m (USD 2.9–5.9m) in the nearest future. ”France is our most underexploited close market,” says Qufora’s CEO.
by peter thomsen, eu correspondent for Watch medier, translated by daniel pedersen
BRUSSELS – the unprofitable market for ensuring more independence for millions of French people in their autumn years will be turned turned into a growth leg in the future, declares Danish medtech firm Qufora, which is betting heavily on exports to the market to its south.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Aging French population could boost Danish health exports
For subscribers
Western medtech exports to Russia pick up speed again
For subscribers
Coloplast initiates trial of ostomy leakage product
For subscribers
.jpg&w=384&q=75)
